



Available online at  
**ScienceDirect**  
www.sciencedirect.com

Elsevier Masson France  
**EM|consulte**  
www.em-consulte.com



ORIGINAL ARTICLE/ARTICLE ORIGINAL

# Vitamin D<sub>3</sub> a new drug against *Candida albicans*

*Vitamine D<sub>3</sub> un nouveau médicament contre Candida albicans*

D. Bouzid<sup>a,\*</sup>, S. Merouki<sup>b</sup>, M. Bachiri<sup>c</sup>, S.E. Ailane<sup>c</sup>,  
M.M. Zerroug<sup>a</sup>

<sup>a</sup> Laboratory of applied microbiology, faculty of nature and life sciences, university Ferhat Abbas Sétif 1, Sétif, Algeria

<sup>b</sup> Laboratory Bouchara Recordati, Alpha Consult, Algeria

<sup>c</sup> Laboratory of microbiology, faculty of sciences, university Mohamed boudiaf, M'sila, Algeria

Received 19 May 2016; accepted 11 October 2016

## KEYWORDS

*Candida albicans*;  
Vitamin D<sub>3</sub>;  
Minimum fungistatic concentrations (MFC<sub>s</sub>);  
Minimum fungicide concentrations (MFC<sub>c</sub>);  
Fungicidal activity

## Summary

**Objective.** – In this study, we demonstrate that vitamin D<sub>3</sub> had fungicidal activity against *Candida albicans*.

**Material and methods.** – The susceptibility of the yeast strain to the vitamin D<sub>3</sub> was investigated by the antimicrobial screening using modified agar diffusion method, minimum fungistatic concentrations (MFC<sub>s</sub>) and minimum fungicide concentrations (MFC<sub>c</sub>) of the vitamin D<sub>3</sub> were determined by the broth dilution method.

**Results.** – The antifungal activity indicated that 100 µg/ml of vitamin D<sub>3</sub> had a power inhibition in the growth of *C. albicans* with zone of inhibition 12.5 mm and CMF<sub>c</sub> and CMF<sub>s</sub> were 1.58 ± 0.0764 µg/ml.

**Conclusion.** – These values indicate that vitamin D<sub>3</sub> can be considered to have fungicide activity. This antifungal effect may be due to the large lipsolubility of vitamin D<sub>3</sub> changing the integrity of the cell membrane.

© 2016 Elsevier Masson SAS. All rights reserved.

## MOTS CLÉS

*Candida albicans* ;  
Vitamine D<sub>3</sub> ;  
Concentrations

## Résumé

**Objectif.** – Dans cette étude, on a démontré que la vitamine D<sub>3</sub> a une activité fongicide contre *Candida albicans*.

**Matériel et méthodes.** – La sensibilité antifongique de la souche de levure à la vitamine D<sub>3</sub> a été étudiée à l'aide de la méthode de diffusion en gélose, les concentrations minimales

\* Corresponding author.

E-mail addresses: [bouzid.djihane@yahoo.fr](mailto:bouzid.djihane@yahoo.fr) (D. Bouzid), [drmerzouki\\_s@yahoo.fr](mailto:drmerzouki_s@yahoo.fr) (S. Merouki), [med.zerroug@gmail.com](mailto:med.zerroug@gmail.com) (M.M. Zerroug).

minimales fongistatiques  
(MFC<sub>s</sub>) ;  
Concentrations  
minimales fongicide  
(MFC<sub>c</sub>) ;  
Activité fongicide

fongistatiques (MFC<sub>s</sub>) et minimales fongicides (MFC<sub>c</sub>) de la vitamine D<sub>3</sub> ont été déterminées par la méthode de dilution en bouillon.

**Résultats.** — L'activité antifongique montre que 100 µg/mL de vitamine D<sub>3</sub> a eu une inhibition sur la croissance de *C. albicans* avec une zone d'inhibition de 12,5 mm et CFM<sub>s</sub> et CFM<sub>c</sub> ayant été 1,58 ± 0,0764 µg/mL.

**Conclusion.** — Ces valeurs indiquent que la vitamine D<sub>3</sub> a une activité fongicide. Cet effet antifongique peut être dû à la grande liposolubilité de la vitamine D<sub>3</sub>, changeant l'intégrité de la membrane cellulaire.

© 2016 Elsevier Masson SAS. Tous droits réservés.

## Introduction

Candidiasis is an infection caused by fungi of the genus *Candida*, being also the most prevalent fungal infections in humans. Candidiasis can manifest both topically and systemically and may involve many different sites in the human body [1].

*Candida* species are commensal microorganisms with a presence that ranges from 20% to 50% of the microorganisms in the oral cavity of the healthy dentate population [2]. *Candida albicans* is regarded as the most pathogenic *Candida* species in all forms of human candidosis [3]. In recent reports, *Candida* spp. remains the leading fungal cause of central line-associated blood stream infections [4].

Although *C. albicans* remains the major species responsible for disseminated candidiasis, a large number of reports have documented infections caused by other *Candida* species [5].

Prolonged prophylaxis or treatment with antifungal agents has increased the incidence of clinical isolates resistant to one or more antifungals in previously susceptible strains [6]. *C. albicans* and *C. tropicalis* were for a long time regarded as species largely susceptible to fluconazole and amphotericin B, but reports over the few last years have shown development of resistance to fluconazole in some centers and clinical therapy failure [7]. The emergence of azole resistance in *Candida* species makes necessary the development of new effective antifungal strategies against drug-resistant strains [8]. It is increasingly recognized that vitamin D<sub>3</sub> plays an important role in pulmonary defense, immunity, and inflammatory processes [9]. Vitamin D<sub>3</sub> insufficiency is associated with an increased risk for several medical conditions, including osteoporotic fractures [10], falls [11], cancer [12], diabetes [13] and hypertension [14]. Immune effects of vitamin D<sub>3</sub> include increased secretion of the antimicrobial peptide cathelicidin, decreased chemokine production, inhibition of dendritic cell activation, and alteration of T-cell activation [15]. But there are no studies on the direct activity of vitamin D<sub>3</sub> on microorganisms, including *C. albicans*.

In the current study, we sought to test this hypothesis by determining the direct sensitivity of *C. albicans* via vitamin D<sub>3</sub>.

## Materials and methods

### Anti-candidal susceptibility testing

Vitamin D<sub>3</sub> provided by Laboratory of Bouchara-Recordati, ampoule of 1 ml contained 200,000 UI, such as 1 µg

equivalent of 40 UI of vitamin D<sub>3</sub>. In this study the vitamin D<sub>3</sub> was individually tested against a yeast *C. albicans* ATCC 10231, provided by University of M'sila. The susceptibility of the yeast strain to the vitamin D<sub>3</sub> was investigated for the antimicrobial screening using two modified methods agar diffusion method [16] and the method of Hayes and Markovic [17].

To prepare the inoculate, yeast cell suspensions were adjusted to match the turbidity of a 0.5-McFarland standard (10<sup>7</sup> CFU/mL) spread on agar plate into Sabouraud dextrose (SDA). Sterile 6-mm filter paper discs (whatman No. 1) were impregnated with 20 µL of the crude vitamin D<sub>3</sub> and were deposited at equal distances on the surface of the inoculated agar Sabraud. Control was used, a negative control with 20 µL of DMSO and an antifungal 5Fluorocytosin (5FC10 µg/ml) as a positive control. Plates were left in at 4 °C for 4 hours before incubation to ensure a good diffusion of the vitamin D<sub>3</sub> in the agar. The diameter of inhibition was measured after 48 h of incubation at 37 °C. The essay was carried out in triplicate.

### Determination of minimum fungistatic concentrations (MFC<sub>s</sub>) and minimum fungicide concentrations (MFC<sub>c</sub>)

(MFC<sub>s</sub>) and (MFC<sub>c</sub>) of the vitamin D<sub>3</sub> were determined by the broth dilution method reported by Bajpai and Kang [18] derived from the original method of Murray et al. [19]. Vitamin D<sub>3</sub> was first diluted in DMSO, from this solution, 2 ml was introduced into a tube containing 18 ml of Sabouraud Dextrose Broth (SDB), containing 0.5% Tween 80. A dilution series were made to the final concentrations (6500 µg/ml to 0,79 µg/ml). 20 µL of yeast suspension (10<sup>7</sup> CFU/mL) tested strain was inoculated in test tubes containing the SDB medium at different concentrations. The mixture, forming the SDB, yeast suspension and the vitamin D<sub>3</sub> is homogenized and incubated at 37 °C for 48 hours. Tubes control containing the middle of SDB, were inoculated with the yeast suspension only. In parallel, the tubes with DMSO and tween 80 (0.5%) were used as negative control. After 48 hours of incubation, the first tubes with total inhibition, compared to the control are reseeded in the boxes containing 20 ml of the SDA culture medium. Growth is tracked for 1–4 days at a temperature of 37 °C. When there is a resumption of growth, concentration is said fungistatic (MFC<sub>s</sub>), on the other hand, if there is no growth; it is called fungicide (MFC<sub>c</sub>). The vitamin D<sub>3</sub> is said to be fungicide when the (MFC<sub>c</sub>)/(MFC<sub>s</sub>) ratio is less than 4, however, when this ratio is higher or equal to 4, it is said to be fungistatic [20].

## Statistical analysis

The analysis of variance was determined by one-way ANOVA and differences among the means were determined for significance at  $P < 0.05$  using a T test.

## Results and discussion

The antifungal activity indicted that 100 µg/ml of vitamin D<sub>3</sub> had a power inhibition in the growth of *C. albicans* with zone of inhibition 12.5 mm and CMF<sub>C</sub> and CMF<sub>S</sub> were 1.58 ± 0.0764 µg/ml. These values indicate that vitamin D<sub>3</sub> had a good antifungal activity. On the basis of the obtained results, the vitamin D<sub>3</sub> can be considered to have fungicide activity. The obtained MFC<sub>C</sub> and MFC<sub>S</sub> which was 1 (less than 4) are similar to those of Derwich et al. [20].

Our results showed that vitamin D<sub>3</sub> demonstrated higher antifungal activity against *C. albicans*. According to Neumann et al. [21] Amphotericin B, the golden standard of antifungal treatment, exhibits higher activity toward ergosterol-rich fungal membranes, which permits its use against systemic mycoses; however, the selectivity for fungal membranes is far from satisfactory leading to severe side effects. The general mechanism of action of vitamin D<sub>3</sub> can be explained by its steroid nature, so any effect disrupts membrane sterols can cause cell lysis. Thus sterols have direct biological activities on sterols of eukaryotic membrane cells including the fungal cells containing ergosterol. This antifungal effect may be due to the large liposolubility of vitamin D<sub>3</sub> changing the integrity of cell membrane. In addition, due to the development of drug resistance as well as side effects of certain antifungal agents, the search for novel antifungal agents has become that more urgent [22]. Most available antifungal agents have fungistatic activities [23]. Thus, discovery of novel antifungal agents with fungicidal activity may be important in developing future treatments [22]. This is the first study on direct contact of vitamin D<sub>3</sub> with *C. albicans* in vitro furthermore we have demonstrated the antifungal effect of vitamin D<sub>3</sub>.

## Conclusion

The present results implicate vitamin D<sub>3</sub> as a potential antifungal agent. The above results suggest that vitamin D<sub>3</sub> can be proposed as a new antifungal drug. Details concerning the mechanism of the antifungal activity of vitamin D<sub>3</sub> on *C. albicans* growth require more.

## Disclosure of interest

The authors declare that they have no competing interest.

## Acknowledgments

This work was supported by a grant from the Algerian government.

## References

[1] Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. *Curr Opin Pharmacol* 2010;10:482–96.

[2] Perezous LF, Flaitz CM, Goldschmidt ME, Engelmeier RL. Colonization of *Candida* species in denture wearers with emphasis on HIV infection: a literature review. *J Prosthet Dent* 2005; 93:288–93.

[3] Williams DW, Jordan RP, Wei XQ, Alves CT, Wise MP, Wilson MJ, et al. Interactions of *Candida albicans* with host epithelial surfaces. *J Oral Microbiol* 2013;5:22434.

[4] Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare associated infections summary of data reported to the National Health care Safety Network at the Centers for Disease Control and Prevention, 2009–2010. *Infect Control Hosp Epidemiol* 2013;34:1–14.

[5] Slavin MA, Sorrell TC, Marriott D, Thursky KA, Nguyen Q, Ellis DH, et al. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. *J Antimicrob Chemother* 2010;65:1042–51.

[6] Sanglard D, Ischer F, Calabrese D, Majcherczyk PA, Bille J. The ATP binding cassette transporter gene CgCDR1 from *Candida glabrata* is involved in the resistance of clinical isolates to azole antifungal agents. *Antimicrob Agents Chemother* 1999;43: 2753–65.

[7] Franz R, Kelly SL, Lamb DC, Kelly DE, Ruhnke M, Morschhauser J. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical *Candida albicans* strains. *Antimicrob Agents Chemother* 1998;42:3065–72.

[8] Warrilow AG, Martel CM, Parker JE, Melo N, Lamb DC, Nes WD, et al. Azole binding properties of *Candida albicans* sterol 14-demethylase (CaCYP51). *Antimicrob Agents Chemother* 2010; 54:4235–45.

[9] Hansdottir S, Monick MM. Vitamin D effects on lung immunity and respiratory diseases. *Vitam Horm* 2011;86:217–37.

[10] Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. *J Clin Endocrinol Metab* 2007;92:1415–23.

[11] Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a metaanalysis. *JAMA* 2004;291: 1999–2006.

[12] Judd SE, Nanes MS, Ziegler TR, Wilson PW, Tangpricha V. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. *Am J Clin Nutr* 2008;87:136–41.

[13] Marins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the third National Health and Nutrition Examination Survey. *Arch Intern Med* 2007;167:1159–65.

[14] Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. *Am J Clin Nutr* 2008;87: 794–1591.

[15] Gow NA, van de Veerdonk FL, Brown AJ, Netea MG. *Candida albicans* morphogenesis and host defence: discriminating invasion from colonization. *Nat Rev Microbiol* 2011;10:112–22.

[16] Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. *Am J Clin Pathol* 1966;45:493–6.

[17] Hayes AJ, Markovic B. Toxicity of australian essential oil *Backhousia citriodora* (Lemon myrtle). Part 1. Antimicrobial activity and in vitro cytotoxicity. *Food Chem Toxicol* 2002;40: 535–43.

[18] Bajpai VK, Kang SC. Antifungal activity of leaf essential oil and extracts of *Metasequoia glyptostroboides Miki* ex. *Hu J Am Oil Chem Soc* 2010;87:327–36.

[19] Murray PR, Baron EJ, Pfaller M, Tenover FC, Tenover RH. Manual of clinical microbiology. Washington: ASM; 1995: 6.

- [20] Derwich E, Benziane Z, Boukir A. GC/MS Analysis and antibacterial activity of the essential oil of *Mentha pulegium* grown in Morocco. *Res J Agric Biol Sci* 2010;6: 191–8.
- [21] Neumann A, Wieczor M, Zielinska J, Baginski M, Czub J. Membrane sterols modulate the binding mode of amphotericin B without affecting its affinity for a lipid bilayer. *Langmuir* 2016;32:3452–61.
- [22] Jeong AL, Hee YC. In vitro antifungal activity of equol against *Candida albicans*. *Mycobiology* 2010;38:328–30.
- [23] Rapp RP. Changing strategies for the management of invasive fungal infections. *Pharmacotherapy* 2004;24:4S–28S.